OncoMatch/Clinical Trials/NCT06702826
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Is NCT06702826 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab combined with SRS for non small cell lung cancer.
Treatment: Cadonilimab combined with SRS — The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-tumor therapy — first-line
Progression with brain metastasis after previous first-line anti-tumor therapy
Must have received: checkpoint inhibitor
Response to previous checkpoint inhibitor therapy on the initial response assessment
Cannot have received: CTLA-4 inhibitor
Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify